查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1677201

按产品、技术平台和最终用户分類的无细胞 DNA 检测市场 - 2025 年至 2030 年全球预测

Cell-Free DNA Testing Market by Offerings, Technology Platform, End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 188 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计2024年无细胞DNA检测市值将达67亿美元，2025年将以7.52%的复合年增长率成长至71.9亿美元，到2030年将达到103.6亿美元。

主要市场统计数据
基准年 2024 年 67亿美元
预计 2025 年 71.9亿美元
预测年份 2030 103.6亿美元
复合年增长率（%） 7.52％

无细胞 DNA（cfDNA）检测已迅速发展成为现代诊断领域的变革工具。该技术从血液和其他体液中提取微量遗传讯息，不仅提供了一种重要的非侵入性检测选择，而且为更早、更准确地检测各种健康状况铺平了道路。在当今的医疗保健领域，无需手术干预即可获取关键遗传资料的能力重新定义了诊断方法并推动了各种临床工作流程的模式转移。

近年来，cfDNA方法取得了重大进展，并被应用于肿瘤学、产前护理、移植监测和传染病检查等多个医学领域。该技术的日益复杂化促使其从小众应用转变为主流诊断资产。高灵敏度平台和创新讯号检测技术的整合不仅提高了这些测试的准确性，而且增强了医疗保健提供者和患者的信心。

本全面概述探讨了 cfDNA 检测如何从早期的希望发展到目前的成熟状态，并研究了关键驱动因素、市场细分和主要区域趋势。这项深入研究的目的是向行业领导者和决策者提供他们所需的洞察力，以便在技术创新迅速和临床期望不断提高的环境中利用这项技术。

改变无细胞 DNA 检测市场

在快速的技术创新和不断变化的临床需求的推动下，cfDNA 检测领域正在转变。在过去几年中，分析技术和分析设计的重大创新重塑了市场格局。透过整合次世代定序、微流体和单分子甲基化分析，可以提高敏感性和特异性，从而改变临床医生进行早期诊断和个人化治疗计划的方式。

从历史上看，侵入性切片检查技术一直是临床诊断的主要手段，但通常具有固有的风险和限制。转向非侵入性cfDNA检测不仅最大限度地降低了这些风险，而且还扩大了在疾病早期获取关键诊断资讯的管道。这种演变在肿瘤学和产前筛检尤其明显，传统方法导致检测速度缓慢且介入困难。

此外，政策转变和监管部门的核准正在增强市场信心，为进一步创新和商业性应用创造有利环境。政府和私人医疗保健组织正在增加对研发计划的投资，以突破cfDNA检测在降低疾病发生率和死亡率方面所能取得的成果。随着分析平台的改进和临床检验研究的增加，cfDNA 检测正在成为精准医疗的基础技术。对于相关人员来说，要驾驭这个不断变化的环境，必须评估影响这个市场未来的机会和挑战。

针对性检查的关键细分见解

对市场细分的详细分析揭示了支持cfDNA检测行业的多面结构。该市场已根据产品范围进行了广泛的研究，包括传染病检查、肿瘤和癌症管理、产前筛检和移植检测。每个领域都解决了重要的诊断需求。在肿瘤学和癌症管理中，重点放在早期检测和筛检，以及微量残存疾病（MRD）评估，以便及时干预和客製化治疗方法。同样，在产前筛检领域，我们区分非侵入性产前检查和胚胎着床前基因检测，为准父母和生育专家提供全面的见解。

此外，基于技术平台的评估描绘了一个高度动态的创新生态系统。市场参与者正在利用各种技术方法，从质谱和微流体到核酸技术、聚合酵素链锁反应（PCR）和单分子甲基化。技术应用的多样性凸显了我们致力于提高分析精度和业务效率的决心。

此外，基于最终用户的细分突显了诊断实验室和检测中心与医院和诊所的不同需求。每个最终用户群体都需要根据其营运规模和临床专业化量身定制的解决方案，从而推动对可自订和整合的测试通讯协定的需求。了解这些细分的细微差别是发现成长机会和设计符合不同临床和业务相关人员不断变化的需求的策略的关键。

目录

第 1 章 简介

第二章调查方法

第三章执行摘要

第四章 市场概况

第五章 市场洞察

  • 市场动态
    • 驱动程式
      • 提高消费者和医生对非侵入性检测益处的认识
      • 为了更安全、更早发现胎儿异常，对非侵入性产前检测的需求日益增长
      • 扩大基因组技术的临床研究
    • 限制因素
      • 定序技术高成本，减少了无细胞 DNA 诊断的机会
    • 机会
      • 政府投资于优先考虑医疗现代化和精准医疗的政策
      • 个人化医疗策略的日益采用为指导治疗计划提供了重要选择。
    • 任务
      • 有关敏感遗传资讯的资料隐私和安全问题
  • 市场区隔分析
    • 提供者：透过使用传染病检查支援快速检测和管理
    • 最终用户：诊断实验室因专注于高通量操作而受到青睐
  • 波特五力分析
  • PESTEL 分析
    • 政治
    • 经济
    • 社会
    • 科技
    • 法律
    • 环境

第 6 章 无细胞 DNA 检测市场（以产品提供）

  • 传染病检查
  • 肿瘤学和癌症管理
    • 早期检测和筛检
    • 微量残存疾病(MRD) 评估
  • 产前筛检
    • 非侵入性产前检测
    • 胚胎着床前基因检测
  • 移植测试

7. 依技术平台分類的无细胞 DNA 检测市场

  • 质谱分析
  • 微流体
  • 核酸技术
  • 聚合酵素链锁反应（PCR）
  • 单分子甲基化

第 8 章。

  • 诊断实验室和检测中心
  • 医院和诊所

9. 美洲无细胞 DNA 检测市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

10. 亚太地区无细胞 DNA 检测市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第 11 章欧洲、中东和非洲无细胞 DNA 检测市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章 竞争格局

  • 2024 年市场占有率分析
  • FPNV 定位矩阵，2024 年
  • 竞争情境分析
  • 战略分析与建议

公司列表

  • Abbott Laboratories
  • Adaptive Biotechnologies Corporation
  • Agilent Technologies, Inc.
  • BGI Genomics Co., Ltd.
  • Biodesix, Inc.
  • Bio-Rad Laboratories, Inc.
  • F. Hoffmann-La Roche
  • Fulgent Genetics, Inc.
  • Guardant Health, Inc.
  • Laboratory Corporation of America Holdings
  • llumina, Inc.
  • Myriad Genetics, Inc.
  • Natera, Inc.
  • OPKO Health, Inc.
  • PerkinElmer, Inc.
  • Qiagen NV
  • Revvity, Inc
  • SOPHiA GENETICS AG
  • Stilla Technologies
  • Thermo Fisher Scientific, Inc.
Product Code: MRR-4772A7539F05

The Cell-Free DNA Testing Market was valued at USD 6.70 billion in 2024 and is projected to grow to USD 7.19 billion in 2025, with a CAGR of 7.52%, reaching USD 10.36 billion by 2030.

KEY MARKET STATISTICS
Base Year [2024] USD 6.70 billion
Estimated Year [2025] USD 7.19 billion
Forecast Year [2030] USD 10.36 billion
CAGR (%) 7.52%

Cell-free DNA (cfDNA) testing has rapidly emerged as a transformative tool within modern diagnostics. This technology, which extracts minute amounts of genetic information from blood or other bodily fluids, not only offers pivotal non-invasive testing options but also paves the way for earlier and more accurate detection of a range of health conditions. In today's healthcare landscape, the ability to capture vital genetic data without the need for surgical interventions has redefined diagnostic practices, fostering a paradigm shift across various clinical workflows.

Recent years have witnessed significant advancements in cfDNA methodologies, leading to its adoption across diverse medical fields including oncology, prenatal care, transplantation monitoring, and infectious disease testing. The growing sophistication of this technology has catalyzed its shift from a niche application to a mainstream diagnostic asset. The integration of high sensitivity platforms and innovative signal detection techniques has not only enhanced the accuracy of these tests but also boosted confidence among healthcare providers and patients alike.

In this comprehensive overview, we explore how cfDNA testing has evolved from its early promise to a current state of maturity, examining key drivers, market segmentations, and leading regional trends. This deep dive aims to equip industry leaders and decision-makers with the insights required to harness this technology in an environment characterized by rapid innovation and heightened clinical expectations.

Transformative Shifts in the Cell-Free DNA Testing Landscape

The landscape of cfDNA testing is undergoing transformative shifts driven by rapid technological advancements and evolving clinical demand. Over the past few years, significant innovations in analytical techniques and assay designs have reshaped the market's architecture. Enhanced sensitivity and specificity, enabled by the integration of next-generation sequencing, microfluidics, and single-molecule methylation analysis, are changing the way clinicians approach early diagnosis and personalized treatment plans.

Historically, invasive biopsy procedures dominated clinical diagnostics, often accompanied by inherent risks and limitations. The shift towards non-invasive cfDNA testing has not only minimized these risks but has also expanded access to critical diagnostic information at earlier stages of disease progression. This evolution is particularly notable in oncology and prenatal screening, where traditional methods have long struggled with late detection and intervention challenges.

Additionally, policy shifts and regulatory approvals have bolstered market confidence, creating an environment conducive to further innovations and commercial adoption. Government and private healthcare entities are increasingly investing in research and development projects to push the boundaries of what cfDNA testing can achieve in reducing disease morbidity and mortality. The convergence of improved analytical platforms and a growing body of clinical validation studies is establishing cfDNA testing as a cornerstone technology in precision medicine. As stakeholders navigate this changing milieu, it becomes imperative to assess both the opportunities and challenges that are shaping this market's future.

Key Segmentation Insights for Targeted and Precision Testing

A granular analysis of market segmentation reveals a multifaceted structure underpinning the cfDNA testing industry. The market is extensively studied based on offerings, which include infectious diseases testing, oncology and cancer management, prenatal screening, and transplantation testing. Each of these areas addresses critical diagnostics needs. In oncology and cancer management, the focus extends further to early detection and screening as well as minimal residual disease (MRD) assessment, allowing for timely intervention and tailored treatment regimens. Similarly, the prenatal screening segment differentiates between non-invasive prenatal testing and preimplantation genetic testing, providing comprehensive insights for expectant parents and fertility specialists.

Moreover, an evaluation based on technology platforms paints a picture of a highly dynamic innovation ecosystem. Market players leverage a range of technological approaches, from mass spectrometry and microfluidics to nucleic acid technology, polymerase chain reaction (PCR), and single-molecule methylation. This diversity in technological application underlines the commitment to enhancing analytical precision and operational efficiency.

Furthermore, the segmentation based on end-users highlights the distinct needs of diagnostic laboratories and testing centers in contrast to hospitals and clinics. Each end-user segment demands solutions tailored to its operational scale and clinical expertise, driving the necessity for customizable and integrative testing protocols. Understanding these segmentation nuances is key to identifying growth opportunities and designing strategies that align with the evolving demands of diverse stakeholders on the clinical and operational fronts.

Based on Offerings, market is studied across Infectious Diseases Testing, Oncology & Cancer Management, Prenatal Screening, and Transplantation Testing. The Oncology & Cancer Management is further studied across Early Detection and Screening and Minimal Residual Disease (MRD) Assessment. The Prenatal Screening is further studied across Non-Invasive Prenatal Testing and Preimplantation Genetic Testing.

Based on Technology Platform, market is studied across Mass Spectrometry, Microfluidics, Nucleic Acid Technology, Polymerase chain reaction (PCR), and Single-molecule Methylation.

Based on End-User, market is studied across Diagnostic Laboratories & Testing Centers and Hospitals & Clinics.

Regional Dynamics: Navigating Global Opportunities and Challenges

Globally, the adoption and evolution of cfDNA testing exhibit varied trends across different regions, each characterized by unique healthcare landscapes and regulatory environments. In the Americas, robust investments in healthcare infrastructure combined with an increasing focus on preventive care have accelerated the integration of cfDNA testing into routine clinical practices. Here, the market benefits from high levels of technological adoption and proactive patient engagement, creating an ecosystem where early diagnosis and personalized medicine are becoming the norm.

The Europe, Middle East & Africa region presents a diverse picture. European markets, with their advanced healthcare systems and regulatory frameworks, have been at the forefront of adopting cutting-edge diagnostic technologies. Simultaneously, emerging markets in the Middle East and Africa are increasingly recognizing the potential of cfDNA testing, driven by rising healthcare demands and initiatives aimed at modernizing diagnostic services. Such dynamics are fostering collaborations between public and private sectors, ensuring that the benefits of early and non-invasive testing reach broader populations.

In the Asia-Pacific region, rapid economic growth and expanding healthcare access are fueling significant market expansion. Countries within this region are investing heavily in technology-driven healthcare solutions, including cfDNA testing. This growth is bolstered by favorable governmental policies, increased R&D activities, and strong collaborations with international biotech companies. While regions continue to face distinct challenges related to infrastructure and regulatory clarity, the underlying momentum towards innovation presents ample opportunities for market players aiming to harness the full potential of cfDNA testing.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Leading Players: Market Innovators and Strategic Movers

The competitive landscape in the cfDNA testing market is marked by the presence of several key industry players who are driving innovation and setting new benchmarks. Companies such as Abbott Laboratories, Adaptive Biotechnologies Corporation, Agilent Technologies, Inc., and BGI Genomics Co., Ltd. have been instrumental in developing advanced testing protocols and expanding market access through robust distribution networks. Their continuous investment in research and development is a testament to their commitment to advancing cfDNA technologies.

Further, prominent organizations including Biodesix, Inc., Bio-Rad Laboratories, Inc., and F. Hoffmann-La Roche are spearheading initiatives that integrate advanced computational analytics with cutting-edge diagnostic tools, bringing enhanced precision to early detection and disease monitoring. Fulgent Genetics, Inc., Guardant Health, Inc., and Laboratory Corporation of America Holdings are also recognized leaders, utilizing their expansive global outreach to deliver reliable non-invasive diagnostic solutions. The market also benefits from the expertise of llumina, Inc., Myriad Genetics, Inc., Natera, Inc., and OPKO Health, Inc., who have all contributed significantly to the evolution of cfDNA testing methodologies.

Additional market momentum is derived from the initiatives of PerkinElmer, Inc., Qiagen N.V., Revvity, Inc, SOPHiA GENETICS AG, Stilla Technologies, and Thermo Fisher Scientific, Inc. These organizations are known for their innovative approaches, especially in integrating advanced technology platforms such as microfluidics and PCR-based systems. The diversified strengths of these companies not only bolster overall market credibility but also stimulate competitive differentiation and continuous improvements in testing efficacy and turnaround times. Their strategic movements reflect a deep understanding of market needs and a proactive approach to overcoming clinical and operational challenges.

The report delves into recent significant developments in the Cell-Free DNA Testing Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Adaptive Biotechnologies Corporation, Agilent Technologies, Inc., BGI Genomics Co., Ltd., Biodesix, Inc., Bio-Rad Laboratories, Inc., F. Hoffmann-La Roche, Fulgent Genetics, Inc., Guardant Health, Inc., Laboratory Corporation of America Holdings, llumina, Inc., Myriad Genetics, Inc., Natera, Inc., OPKO Health, Inc., PerkinElmer, Inc., Qiagen N.V., Revvity, Inc, SOPHiA GENETICS AG, Stilla Technologies, and Thermo Fisher Scientific, Inc.. Actionable Recommendations for Industry Leaders

Industry leaders stand at the nexus of innovation and market transformation. It is crucial to adopt an integrative strategy that blends technological advancements with insights drawn from comprehensive market segmentation. Leaders should prioritize investment in cutting-edge analytical platforms while embracing cross-sector collaborations, thereby enhancing the accuracy and reliability of cfDNA testing. Strategic partnerships with technology innovators and clinical research institutions can also bridge the gap between emerging diagnostic capabilities and established healthcare practices.

In addition, focusing on personalized diagnostic approaches will not only cater to the specific demands of various patient populations but also secure a competitive edge in a rapidly evolving market. It is advisable to continuously monitor regulatory developments and leverage data-driven insights to optimize test deployment strategies, ensuring adaptable and scalable solutions that meet both current and future market needs.

Conclusion: Synthesis and Future Outlook

The journey of cfDNA testing from an experimental diagnostic tool to a mainstream clinical asset underscores its transformative potential. The convergence of technological innovations, diverse market segmentations, and dynamic regional trends is reshaping diagnostic paradigms across the globe. Insights into specific market segments, technological platforms, and end-user demands illustrate a landscape characterized by both opportunity and complexity.

As the market continues its upward trajectory, stakeholders are encouraged to adopt forward-thinking approaches that integrate advanced analytics, collaborative ventures, and strategic foresight. The future of cfDNA testing is promising, with sustained advancements poised to further enhance the scope of non-invasive diagnostics and contribute to improved clinical outcomes.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising consumer and physician awareness regarding non-invasive testing benefits
      • 5.1.1.2. Growing demand for non-invasive prenatal testing to ensure safer and earlier detection of fetal abnormalities
      • 5.1.1.3. Expanding clinical research in genomic technologies
    • 5.1.2. Restraints
      • 5.1.2.1. High costs of sequencing technology reducing accessibility for cell free DNA diagnostics
    • 5.1.3. Opportunities
      • 5.1.3.1. Government investments in healthcare modernization and policies favoring precision medicine
      • 5.1.3.2. Increasing adoption of personalized medicine strategies is creating significant options for guiding treatment planning
    • 5.1.4. Challenges
      • 5.1.4.1. Data privacy and security concerns related to sensitive genetic information
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Offerings: Utilization of infectious disease testing for rapid detection and aiding in the management
    • 5.2.2. End-User: Preference for diagnostic laboratories due to their focus on high-throughput operations
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Cell-Free DNA Testing Market, by Offerings

  • 6.1. Introduction
  • 6.2. Infectious Diseases Testing
  • 6.3. Oncology & Cancer Management
    • 6.3.1. Early Detection and Screening
    • 6.3.2. Minimal Residual Disease (MRD) Assessment
  • 6.4. Prenatal Screening
    • 6.4.1. Non-Invasive Prenatal Testing
    • 6.4.2. Preimplantation Genetic Testing
  • 6.5. Transplantation Testing

7. Cell-Free DNA Testing Market, by Technology Platform

  • 7.1. Introduction
  • 7.2. Mass Spectrometry
  • 7.3. Microfluidics
  • 7.4. Nucleic Acid Technology
  • 7.5. Polymerase chain reaction (PCR)
  • 7.6. Single-molecule Methylation

8. Cell-Free DNA Testing Market, by End-User

  • 8.1. Introduction
  • 8.2. Diagnostic Laboratories & Testing Centers
  • 8.3. Hospitals & Clinics

9. Americas Cell-Free DNA Testing Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Cell-Free DNA Testing Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Cell-Free DNA Testing Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2024
  • 12.2. FPNV Positioning Matrix, 2024
  • 12.3. Competitive Scenario Analysis
    • 12.3.1. Aldevron unveils alchemy, a rapid, purified cell-free DNA technology
    • 12.3.2. Natera expands reproductive health testing with strategic acquisition
    • 12.3.3. Natera secures USD 250M to accelerate personalized cfDNA testing
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. Adaptive Biotechnologies Corporation
  • 3. Agilent Technologies, Inc.
  • 4. BGI Genomics Co., Ltd.
  • 5. Biodesix, Inc.
  • 6. Bio-Rad Laboratories, Inc.
  • 7. F. Hoffmann-La Roche
  • 8. Fulgent Genetics, Inc.
  • 9. Guardant Health, Inc.
  • 10. Laboratory Corporation of America Holdings
  • 11. llumina, Inc.
  • 12. Myriad Genetics, Inc.
  • 13. Natera, Inc.
  • 14. OPKO Health, Inc.
  • 15. PerkinElmer, Inc.
  • 16. Qiagen N.V.
  • 17. Revvity, Inc
  • 18. SOPHiA GENETICS AG
  • 19. Stilla Technologies
  • 20. Thermo Fisher Scientific, Inc.

LIST OF FIGURES

  • FIGURE 1. CELL-FREE DNA TESTING MARKET MULTI-CURRENCY
  • FIGURE 2. CELL-FREE DNA TESTING MARKET MULTI-LANGUAGE
  • FIGURE 3. CELL-FREE DNA TESTING MARKET RESEARCH PROCESS
  • FIGURE 4. CELL-FREE DNA TESTING MARKET SIZE, 2024 VS 2030
  • FIGURE 5. GLOBAL CELL-FREE DNA TESTING MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 6. GLOBAL CELL-FREE DNA TESTING MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL CELL-FREE DNA TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL CELL-FREE DNA TESTING MARKET SIZE, BY OFFERINGS, 2024 VS 2030 (%)
  • FIGURE 9. GLOBAL CELL-FREE DNA TESTING MARKET SIZE, BY OFFERINGS, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL CELL-FREE DNA TESTING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2024 VS 2030 (%)
  • FIGURE 11. GLOBAL CELL-FREE DNA TESTING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL CELL-FREE DNA TESTING MARKET SIZE, BY END-USER, 2024 VS 2030 (%)
  • FIGURE 13. GLOBAL CELL-FREE DNA TESTING MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS CELL-FREE DNA TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 15. AMERICAS CELL-FREE DNA TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES CELL-FREE DNA TESTING MARKET SIZE, BY STATE, 2024 VS 2030 (%)
  • FIGURE 17. UNITED STATES CELL-FREE DNA TESTING MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC CELL-FREE DNA TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC CELL-FREE DNA TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA CELL-FREE DNA TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA CELL-FREE DNA TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 22. CELL-FREE DNA TESTING MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 23. CELL-FREE DNA TESTING MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. CELL-FREE DNA TESTING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL CELL-FREE DNA TESTING MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL CELL-FREE DNA TESTING MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL CELL-FREE DNA TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. CELL-FREE DNA TESTING MARKET DYNAMICS
  • TABLE 7. GLOBAL CELL-FREE DNA TESTING MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL CELL-FREE DNA TESTING MARKET SIZE, BY INFECTIOUS DISEASES TESTING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL CELL-FREE DNA TESTING MARKET SIZE, BY ONCOLOGY & CANCER MANAGEMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL CELL-FREE DNA TESTING MARKET SIZE, BY EARLY DETECTION AND SCREENING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL CELL-FREE DNA TESTING MARKET SIZE, BY MINIMAL RESIDUAL DISEASE (MRD) ASSESSMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL CELL-FREE DNA TESTING MARKET SIZE, BY ONCOLOGY & CANCER MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL CELL-FREE DNA TESTING MARKET SIZE, BY PRENATAL SCREENING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL CELL-FREE DNA TESTING MARKET SIZE, BY NON-INVASIVE PRENATAL TESTING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL CELL-FREE DNA TESTING MARKET SIZE, BY PREIMPLANTATION GENETIC TESTING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL CELL-FREE DNA TESTING MARKET SIZE, BY PRENATAL SCREENING, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL CELL-FREE DNA TESTING MARKET SIZE, BY TRANSPLANTATION TESTING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL CELL-FREE DNA TESTING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL CELL-FREE DNA TESTING MARKET SIZE, BY MASS SPECTROMETRY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL CELL-FREE DNA TESTING MARKET SIZE, BY MICROFLUIDICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL CELL-FREE DNA TESTING MARKET SIZE, BY NUCLEIC ACID TECHNOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL CELL-FREE DNA TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL CELL-FREE DNA TESTING MARKET SIZE, BY SINGLE-MOLECULE METHYLATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL CELL-FREE DNA TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL CELL-FREE DNA TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES & TESTING CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL CELL-FREE DNA TESTING MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS CELL-FREE DNA TESTING MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS CELL-FREE DNA TESTING MARKET SIZE, BY ONCOLOGY & CANCER MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS CELL-FREE DNA TESTING MARKET SIZE, BY PRENATAL SCREENING, 2018-2030 (USD MILLION)
  • TABLE 30. AMERICAS CELL-FREE DNA TESTING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
  • TABLE 31. AMERICAS CELL-FREE DNA TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 32. AMERICAS CELL-FREE DNA TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 33. ARGENTINA CELL-FREE DNA TESTING MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
  • TABLE 34. ARGENTINA CELL-FREE DNA TESTING MARKET SIZE, BY ONCOLOGY & CANCER MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 35. ARGENTINA CELL-FREE DNA TESTING MARKET SIZE, BY PRENATAL SCREENING, 2018-2030 (USD MILLION)
  • TABLE 36. ARGENTINA CELL-FREE DNA TESTING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
  • TABLE 37. ARGENTINA CELL-FREE DNA TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 38. BRAZIL CELL-FREE DNA TESTING MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
  • TABLE 39. BRAZIL CELL-FREE DNA TESTING MARKET SIZE, BY ONCOLOGY & CANCER MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 40. BRAZIL CELL-FREE DNA TESTING MARKET SIZE, BY PRENATAL SCREENING, 2018-2030 (USD MILLION)
  • TABLE 41. BRAZIL CELL-FREE DNA TESTING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
  • TABLE 42. BRAZIL CELL-FREE DNA TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 43. CANADA CELL-FREE DNA TESTING MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
  • TABLE 44. CANADA CELL-FREE DNA TESTING MARKET SIZE, BY ONCOLOGY & CANCER MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 45. CANADA CELL-FREE DNA TESTING MARKET SIZE, BY PRENATAL SCREENING, 2018-2030 (USD MILLION)
  • TABLE 46. CANADA CELL-FREE DNA TESTING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
  • TABLE 47. CANADA CELL-FREE DNA TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 48. MEXICO CELL-FREE DNA TESTING MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
  • TABLE 49. MEXICO CELL-FREE DNA TESTING MARKET SIZE, BY ONCOLOGY & CANCER MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 50. MEXICO CELL-FREE DNA TESTING MARKET SIZE, BY PRENATAL SCREENING, 2018-2030 (USD MILLION)
  • TABLE 51. MEXICO CELL-FREE DNA TESTING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
  • TABLE 52. MEXICO CELL-FREE DNA TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 53. UNITED STATES CELL-FREE DNA TESTING MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
  • TABLE 54. UNITED STATES CELL-FREE DNA TESTING MARKET SIZE, BY ONCOLOGY & CANCER MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 55. UNITED STATES CELL-FREE DNA TESTING MARKET SIZE, BY PRENATAL SCREENING, 2018-2030 (USD MILLION)
  • TABLE 56. UNITED STATES CELL-FREE DNA TESTING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
  • TABLE 57. UNITED STATES CELL-FREE DNA TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 58. UNITED STATES CELL-FREE DNA TESTING MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 59. ASIA-PACIFIC CELL-FREE DNA TESTING MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
  • TABLE 60. ASIA-PACIFIC CELL-FREE DNA TESTING MARKET SIZE, BY ONCOLOGY & CANCER MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 61. ASIA-PACIFIC CELL-FREE DNA TESTING MARKET SIZE, BY PRENATAL SCREENING, 2018-2030 (USD MILLION)
  • TABLE 62. ASIA-PACIFIC CELL-FREE DNA TESTING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
  • TABLE 63. ASIA-PACIFIC CELL-FREE DNA TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 64. ASIA-PACIFIC CELL-FREE DNA TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 65. AUSTRALIA CELL-FREE DNA TESTING MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
  • TABLE 66. AUSTRALIA CELL-FREE DNA TESTING MARKET SIZE, BY ONCOLOGY & CANCER MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 67. AUSTRALIA CELL-FREE DNA TESTING MARKET SIZE, BY PRENATAL SCREENING, 2018-2030 (USD MILLION)
  • TABLE 68. AUSTRALIA CELL-FREE DNA TESTING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
  • TABLE 69. AUSTRALIA CELL-FREE DNA TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 70. CHINA CELL-FREE DNA TESTING MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
  • TABLE 71. CHINA CELL-FREE DNA TESTING MARKET SIZE, BY ONCOLOGY & CANCER MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 72. CHINA CELL-FREE DNA TESTING MARKET SIZE, BY PRENATAL SCREENING, 2018-2030 (USD MILLION)
  • TABLE 73. CHINA CELL-FREE DNA TESTING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
  • TABLE 74. CHINA CELL-FREE DNA TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 75. INDIA CELL-FREE DNA TESTING MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
  • TABLE 76. INDIA CELL-FREE DNA TESTING MARKET SIZE, BY ONCOLOGY & CANCER MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 77. INDIA CELL-FREE DNA TESTING MARKET SIZE, BY PRENATAL SCREENING, 2018-2030 (USD MILLION)
  • TABLE 78. INDIA CELL-FREE DNA TESTING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
  • TABLE 79. INDIA CELL-FREE DNA TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 80. INDONESIA CELL-FREE DNA TESTING MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
  • TABLE 81. INDONESIA CELL-FREE DNA TESTING MARKET SIZE, BY ONCOLOGY & CANCER MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 82. INDONESIA CELL-FREE DNA TESTING MARKET SIZE, BY PRENATAL SCREENING, 2018-2030 (USD MILLION)
  • TABLE 83. INDONESIA CELL-FREE DNA TESTING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
  • TABLE 84. INDONESIA CELL-FREE DNA TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 85. JAPAN CELL-FREE DNA TESTING MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
  • TABLE 86. JAPAN CELL-FREE DNA TESTING MARKET SIZE, BY ONCOLOGY & CANCER MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 87. JAPAN CELL-FREE DNA TESTING MARKET SIZE, BY PRENATAL SCREENING, 2018-2030 (USD MILLION)
  • TABLE 88. JAPAN CELL-FREE DNA TESTING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
  • TABLE 89. JAPAN CELL-FREE DNA TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 90. MALAYSIA CELL-FREE DNA TESTING MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
  • TABLE 91. MALAYSIA CELL-FREE DNA TESTING MARKET SIZE, BY ONCOLOGY & CANCER MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 92. MALAYSIA CELL-FREE DNA TESTING MARKET SIZE, BY PRENATAL SCREENING, 2018-2030 (USD MILLION)
  • TABLE 93. MALAYSIA CELL-FREE DNA TESTING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
  • TABLE 94. MALAYSIA CELL-FREE DNA TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 95. PHILIPPINES CELL-FREE DNA TESTING MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
  • TABLE 96. PHILIPPINES CELL-FREE DNA TESTING MARKET SIZE, BY ONCOLOGY & CANCER MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 97. PHILIPPINES CELL-FREE DNA TESTING MARKET SIZE, BY PRENATAL SCREENING, 2018-2030 (USD MILLION)
  • TABLE 98. PHILIPPINES CELL-FREE DNA TESTING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
  • TABLE 99. PHILIPPINES CELL-FREE DNA TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 100. SINGAPORE CELL-FREE DNA TESTING MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
  • TABLE 101. SINGAPORE CELL-FREE DNA TESTING MARKET SIZE, BY ONCOLOGY & CANCER MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 102. SINGAPORE CELL-FREE DNA TESTING MARKET SIZE, BY PRENATAL SCREENING, 2018-2030 (USD MILLION)
  • TABLE 103. SINGAPORE CELL-FREE DNA TESTING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
  • TABLE 104. SINGAPORE CELL-FREE DNA TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 105. SOUTH KOREA CELL-FREE DNA TESTING MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
  • TABLE 106. SOUTH KOREA CELL-FREE DNA TESTING MARKET SIZE, BY ONCOLOGY & CANCER MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 107. SOUTH KOREA CELL-FREE DNA TESTING MARKET SIZE, BY PRENATAL SCREENING, 2018-2030 (USD MILLION)
  • TABLE 108. SOUTH KOREA CELL-FREE DNA TESTING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
  • TABLE 109. SOUTH KOREA CELL-FREE DNA TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 110. TAIWAN CELL-FREE DNA TESTING MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
  • TABLE 111. TAIWAN CELL-FREE DNA TESTING MARKET SIZE, BY ONCOLOGY & CANCER MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 112. TAIWAN CELL-FREE DNA TESTING MARKET SIZE, BY PRENATAL SCREENING, 2018-2030 (USD MILLION)
  • TABLE 113. TAIWAN CELL-FREE DNA TESTING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
  • TABLE 114. TAIWAN CELL-FREE DNA TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 115. THAILAND CELL-FREE DNA TESTING MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
  • TABLE 116. THAILAND CELL-FREE DNA TESTING MARKET SIZE, BY ONCOLOGY & CANCER MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 117. THAILAND CELL-FREE DNA TESTING MARKET SIZE, BY PRENATAL SCREENING, 2018-2030 (USD MILLION)
  • TABLE 118. THAILAND CELL-FREE DNA TESTING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
  • TABLE 119. THAILAND CELL-FREE DNA TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 120. VIETNAM CELL-FREE DNA TESTING MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
  • TABLE 121. VIETNAM CELL-FREE DNA TESTING MARKET SIZE, BY ONCOLOGY & CANCER MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 122. VIETNAM CELL-FREE DNA TESTING MARKET SIZE, BY PRENATAL SCREENING, 2018-2030 (USD MILLION)
  • TABLE 123. VIETNAM CELL-FREE DNA TESTING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
  • TABLE 124. VIETNAM CELL-FREE DNA TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 125. EUROPE, MIDDLE EAST & AFRICA CELL-FREE DNA TESTING MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
  • TABLE 126. EUROPE, MIDDLE EAST & AFRICA CELL-FREE DNA TESTING MARKET SIZE, BY ONCOLOGY & CANCER MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 127. EUROPE, MIDDLE EAST & AFRICA CELL-FREE DNA TESTING MARKET SIZE, BY PRENATAL SCREENING, 2018-2030 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA CELL-FREE DNA TESTING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA CELL-FREE DNA TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 130. EUROPE, MIDDLE EAST & AFRICA CELL-FREE DNA TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 131. DENMARK CELL-FREE DNA TESTING MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
  • TABLE 132. DENMARK CELL-FREE DNA TESTING MARKET SIZE, BY ONCOLOGY & CANCER MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 133. DENMARK CELL-FREE DNA TESTING MARKET SIZE, BY PRENATAL SCREENING, 2018-2030 (USD MILLION)
  • TABLE 134. DENMARK CELL-FREE DNA TESTING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
  • TABLE 135. DENMARK CELL-FREE DNA TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 136. EGYPT CELL-FREE DNA TESTING MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
  • TABLE 137. EGYPT CELL-FREE DNA TESTING MARKET SIZE, BY ONCOLOGY & CANCER MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 138. EGYPT CELL-FREE DNA TESTING MARKET SIZE, BY PRENATAL SCREENING, 2018-2030 (USD MILLION)
  • TABLE 139. EGYPT CELL-FREE DNA TESTING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
  • TABLE 140. EGYPT CELL-FREE DNA TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 141. FINLAND CELL-FREE DNA TESTING MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
  • TABLE 142. FINLAND CELL-FREE DNA TESTING MARKET SIZE, BY ONCOLOGY & CANCER MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 143. FINLAND CELL-FREE DNA TESTING MARKET SIZE, BY PRENATAL SCREENING, 2018-2030 (USD MILLION)
  • TABLE 144. FINLAND CELL-FREE DNA TESTING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
  • TABLE 145. FINLAND CELL-FREE DNA TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 146. FRANCE CELL-FREE DNA TESTING MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
  • TABLE 147. FRANCE CELL-FREE DNA TESTING MARKET SIZE, BY ONCOLOGY & CANCER MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 148. FRANCE CELL-FREE DNA TESTING MARKET SIZE, BY PRENATAL SCREENING, 2018-2030 (USD MILLION)
  • TABLE 149. FRANCE CELL-FREE DNA TESTING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
  • TABLE 150. FRANCE CELL-FREE DNA TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 151. GERMANY CELL-FREE DNA TESTING MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
  • TABLE 152. GERMANY CELL-FREE DNA TESTING MARKET SIZE, BY ONCOLOGY & CANCER MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 153. GERMANY CELL-FREE DNA TESTING MARKET SIZE, BY PRENATAL SCREENING, 2018-2030 (USD MILLION)
  • TABLE 154. GERMANY CELL-FREE DNA TESTING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
  • TABLE 155. GERMANY CELL-FREE DNA TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 156. ISRAEL CELL-FREE DNA TESTING MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
  • TABLE 157. ISRAEL CELL-FREE DNA TESTING MARKET SIZE, BY ONCOLOGY & CANCER MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 158. ISRAEL CELL-FREE DNA TESTING MARKET SIZE, BY PRENATAL SCREENING, 2018-2030 (USD MILLION)
  • TABLE 159. ISRAEL CELL-FREE DNA TESTING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
  • TABLE 160. ISRAEL CELL-FREE DNA TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 161. ITALY CELL-FREE DNA TESTING MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
  • TABLE 162. ITALY CELL-FREE DNA TESTING MARKET SIZE, BY ONCOLOGY & CANCER MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 163. ITALY CELL-FREE DNA TESTING MARKET SIZE, BY PRENATAL SCREENING, 2018-2030 (USD MILLION)
  • TABLE 164. ITALY CELL-FREE DNA TESTING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
  • TABLE 165. ITALY CELL-FREE DNA TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 166. NETHERLANDS CELL-FREE DNA TESTING MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
  • TABLE 167. NETHERLANDS CELL-FREE DNA TESTING MARKET SIZE, BY ONCOLOGY & CANCER MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 168. NETHERLANDS CELL-FREE DNA TESTING MARKET SIZE, BY PRENATAL SCREENING, 2018-2030 (USD MILLION)
  • TABLE 169. NETHERLANDS CELL-FREE DNA TESTING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
  • TABLE 170. NETHERLANDS CELL-FREE DNA TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 171. NIGERIA CELL-FREE DNA TESTING MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
  • TABLE 172. NIGERIA CELL-FREE DNA TESTING MARKET SIZE, BY ONCOLOGY & CANCER MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 173. NIGERIA CELL-FREE DNA TESTING MARKET SIZE, BY PRENATAL SCREENING, 2018-2030 (USD MILLION)
  • TABLE 174. NIGERIA CELL-FREE DNA TESTING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
  • TABLE 175. NIGERIA CELL-FREE DNA TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 176. NORWAY CELL-FREE DNA TESTING MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
  • TABLE 177. NORWAY CELL-FREE DNA TESTING MARKET SIZE, BY ONCOLOGY & CANCER MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 178. NORWAY CELL-FREE DNA TESTING MARKET SIZE, BY PRENATAL SCREENING, 2018-2030 (USD MILLION)
  • TABLE 179. NORWAY CELL-FREE DNA TESTING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
  • TABLE 180. NORWAY CELL-FREE DNA TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 181. POLAND CELL-FREE DNA TESTING MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
  • TABLE 182. POLAND CELL-FREE DNA TESTING MARKET SIZE, BY ONCOLOGY & CANCER MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 183. POLAND CELL-FREE DNA TESTING MARKET SIZE, BY PRENATAL SCREENING, 2018-2030 (USD MILLION)
  • TABLE 184. POLAND CELL-FREE DNA TESTING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
  • TABLE 185. POLAND CELL-FREE DNA TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 186. QATAR CELL-FREE DNA TESTING MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
  • TABLE 187. QATAR CELL-FREE DNA TESTING MARKET SIZE, BY ONCOLOGY & CANCER MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 188. QATAR CELL-FREE DNA TESTING MARKET SIZE, BY PRENATAL SCREENING, 2018-2030 (USD MILLION)
  • TABLE 189. QATAR CELL-FREE DNA TESTING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
  • TABLE 190. QATAR CELL-FREE DNA TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 191. RUSSIA CELL-FREE DNA TESTING MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
  • TABLE 192. RUSSIA CELL-FREE DNA TESTING MARKET SIZE, BY ONCOLOGY & CANCER MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 193. RUSSIA CELL-FREE DNA TESTING MARKET SIZE, BY PRENATAL SCREENING, 2018-2030 (USD MILLION)
  • TABLE 194. RUSSIA CELL-FREE DNA TESTING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
  • TABLE 195. RUSSIA CELL-FREE DNA TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 196. SAUDI ARABIA CELL-FREE DNA TESTING MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
  • TABLE 197. SAUDI ARABIA CELL-FREE DNA TESTING MARKET SIZE, BY ONCOLOGY & CANCER MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 198. SAUDI ARABIA CELL-FREE DNA TESTING MARKET SIZE, BY PRENATAL SCREENING, 2018-2030 (USD MILLION)
  • TABLE 199. SAUDI ARABIA CELL-FREE DNA TESTING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
  • TABLE 200. SAUDI ARABIA CELL-FREE DNA TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 201. SOUTH AFRICA CELL-FREE DNA TESTING MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
  • TABLE 202. SOUTH AFRICA CELL-FREE DNA TESTING MARKET SIZE, BY ONCOLOGY & CANCER MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 203. SOUTH AFRICA CELL-FREE DNA TESTING MARKET SIZE, BY PRENATAL SCREENING, 2018-2030 (USD MILLION)
  • TABLE 204. SOUTH AFRICA CELL-FREE DNA TESTING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
  • TABLE 205. SOUTH AFRICA CELL-FREE DNA TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 206. SPAIN CELL-FREE DNA TESTING MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
  • TABLE 207. SPAIN CELL-FREE DNA TESTING MARKET SIZE, BY ONCOLOGY & CANCER MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 208. SPAIN CELL-FREE DNA TESTING MARKET SIZE, BY PRENATAL SCREENING, 2018-2030 (USD MILLION)
  • TABLE 209. SPAIN CELL-FREE DNA TESTING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
  • TABLE 210. SPAIN CELL-FREE DNA TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 211. SWEDEN CELL-FREE DNA TESTING MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
  • TABLE 212. SWEDEN CELL-FREE DNA TESTING MARKET SIZE, BY ONCOLOGY & CANCER MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 213. SWEDEN CELL-FREE DNA TESTING MARKET SIZE, BY PRENATAL SCREENING, 2018-2030 (USD MILLION)
  • TABLE 214. SWEDEN CELL-FREE DNA TESTING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
  • TABLE 215. SWEDEN CELL-FREE DNA TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 216. SWITZERLAND CELL-FREE DNA TESTING MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
  • TABLE 217. SWITZERLAND CELL-FREE DNA TESTING MARKET SIZE, BY ONCOLOGY & CANCER MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 218. SWITZERLAND CELL-FREE DNA TESTING MARKET SIZE, BY PRENATAL SCREENING, 2018-2030 (USD MILLION)
  • TABLE 219. SWITZERLAND CELL-FREE DNA TESTING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
  • TABLE 220. SWITZERLAND CELL-FREE DNA TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 221. TURKEY CELL-FREE DNA TESTING MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
  • TABLE 222. TURKEY CELL-FREE DNA TESTING MARKET SIZE, BY ONCOLOGY & CANCER MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 223. TURKEY CELL-FREE DNA TESTING MARKET SIZE, BY PRENATAL SCREENING, 2018-2030 (USD MILLION)
  • TABLE 224. TURKEY CELL-FREE DNA TESTING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
  • TABLE 225. TURKEY CELL-FREE DNA TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 226. UNITED ARAB EMIRATES CELL-FREE DNA TESTING MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
  • TABLE 227. UNITED ARAB EMIRATES CELL-FREE DNA TESTING MARKET SIZE, BY ONCOLOGY & CANCER MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 228. UNITED ARAB EMIRATES CELL-FREE DNA TESTING MARKET SIZE, BY PRENATAL SCREENING, 2018-2030 (USD MILLION)
  • TABLE 229. UNITED ARAB EMIRATES CELL-FREE DNA TESTING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
  • TABLE 230. UNITED ARAB EMIRATES CELL-FREE DNA TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 231. UNITED KINGDOM CELL-FREE DNA TESTING MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
  • TABLE 232. UNITED KINGDOM CELL-FREE DNA TESTING MARKET SIZE, BY ONCOLOGY & CANCER MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 233. UNITED KINGDOM CELL-FREE DNA TESTING MARKET SIZE, BY PRENATAL SCREENING, 2018-2030 (USD MILLION)
  • TABLE 234. UNITED KINGDOM CELL-FREE DNA TESTING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
  • TABLE 235. UNITED KINGDOM CELL-FREE DNA TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 236. CELL-FREE DNA TESTING MARKET SHARE, BY KEY PLAYER, 2024
  • TABLE 237. CELL-FREE DNA TESTING MARKET, FPNV POSITIONING MATRIX, 2024